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Toll-like receptors (TLRs) are important in barrier homeostasis, but their role in airborne allergies is not fully under-
stood. The aim was to evaluate baseline and allergen-induced expression of TLR proteins in nasal epithelium during
allergic rhinitis. Nineteen otherwise healthy non-smoking volunteers both allergic to birch pollen and non-allergic con-
trols were enrolled. We took nasal biopsies before and after oﬀ-seasonal intranasal birch pollen or diluent challenge.
The expression of epithelial TLR1-7, TLR9-10, and MyD88 proteins was immunohistochemically evaluated from the
nasal biopsies. The TLR1-3 and TLR5-10 mRNAs were observed by RNA-microarray. Baseline epithelial expression
of TLR proteins was wide and identical in controls and atopics. After oﬀ-seasonal intranasal birch pollen challenge, a
negative change in the expression score of TLR1 and TLR6 proteins was detected in the atopic group. TLR mRNA
expression was not aﬀected by birch pollen challenge. Nasal epithelium seems to express all known TLRs. The mecha-
nisms by which TLR1, and TLR6 proteins could aﬀect pollen allergen transport need further studies.
Key words: Allergic rhinitis; challenge; epithelium; immunohistochemistry; toll-like receptor.
Sanna Toppila-Salmi, Transplantation Laboratory, Haartman Institute, University of Helsinki, PO Box 21, Haartman-
inkatu 3, Helsinki FI 00014, Finland. e-mail: sanna.salmi@helsinki.ﬁ
†These authors have contributed equally to this work.
Birch pollen allergic rhinitis is the most common
allergic disorder in the Northern Europe, with a
prevalence of 15–20% (1, 2). Epigenetic and genetic
modiﬁcations of innate immunity together with
microbial and other environmental stimuli may pre-
dispose to airway allergy (3, 4). Many intrinsic and
environmental factors facilitate the entry of air-
borne allergens in the respiratory mucosa (3). Epi-
thelial cells produce mediators, which aﬀect the
recruitment and activation of more specialized
immune cells and create a microenvironment where
these activated immune cells may function and
propagate the inﬂammatory processes (5).
Innate immunity by pathogen recognition is a
pivotal defense system. Its aim is fast detection of
pathogens from the environment when they get into
contact with the organisms. At least four classes of
pattern recognition receptors (PRRs) identiﬁed to
date are critical for sensing microorganisms and for
the subsequent stimulation of proinﬂammatory
responses: toll-like receptors (TLRs), nucleotide
oligomerization domain-like receptors, RIG-I-like
receptors, and C type lectin receptors (6). Human
TLRs are a large family with at least eleven
members (5). TLRs sense a large diversity of patho-
gen-associated molecular patterns from various
intruders such as bacteria and viruses, bacterial
lipopolysaccharide (LPS), lipoproteins, peptidogly-Received 4 January 2015. Accepted 24 April 2015
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cans, bacterial DNA, and double-stranded RNA
(7–10). TLR1, TLR2, TLR4, TLR5, TLR6, and
TLR10 are expressed on the epithelial cell surface
and recognize the pathogen-associated molecular
patterns of extracellular microbes (8, 11–13). TLR3,
TLR7, TLR8, and TLR9 are localized within the
intracellular endolysosomal compartments and are
involved in the recognition of nucleic acids. TLR3
utilizes exclusively the TRIF-dependent pathway.
The signals of other TLRs utilize the MyD88-
dependent pathways as well (14). For instance,
upon recognition of LPS on the cell surface, TLR4
ﬁrst induces the TIRAP/MyD88 signaling on the
plasma membrane and is thereafter endocytosed.
Next TRAM-TRIF is activated in early endosomes
leading to induction of type-I interferons (7–11).
Under normal conditions commensal bacteria are
recognized by TLRs and this recognition is essential
for the maintenance of homeostasis and a state of
constant controlled inﬂammation (15). Diﬀerent
mutations and experimental models, which alter the
TLR functions, have demonstrated the signiﬁcance
of TLRs in susceptibility to infection (16–18). TLRs
are also reported to be involved in the pathogenesis
of a large number of inﬂammatory disorders, such
as asthma and allergy (13), chronic rhinosinusitis
(19), inﬂammatory bowel disease (20), atherosclero-
sis (21), and obesity (22). Meta-analyses of genome-
wide studies indicate that loci in the region TLR1-
TLR6-TLR10 might associate with atopic sensitiza-
tion or reported allergy (23, 24). Der p 2, the main
house dust mite allergen, has shown to mimic MD2
like the chaperone that promotes TLR4 signaling
(25). Previous studies show that the following TLRs
might be related with grass or birch pollen allergic
rhinitis: TLR1, TLR2, TLR6, TLR7, TLR8, and
TLR10 (23, 26–29).
We previously demonstrated that birch pollen
allergic patients might have reduced immune
response in their nasal epithelium (30). This could
putatively lead to an active epithelial transport of
birch pollen allergens detected only in patients
allergic to birch pollen (31). The aim of this study
was to evaluate whether the baseline epithelial
expression of TLRs and MyD88 diﬀer between
healthy and birch pollen allergic subjects. More-
over, we aimed at detecting allergen-induced early
alterations in the expression of TLRs and MyD88.
MATERIALS AND METHODS
Subjects
This study was carried out at the University of Helsinki and
Tampere University Hospital in 2007-08. It was approved by
the Ethical Committee of the Hospital District of Pirkanmaa
(nro. R04044), and was performed according to the Declara-
tion of Helsinki. Written informed consent was obtained
from all subjects. Nineteen subjects (nine allergic and 10
healthy) participated in the study (Table 1). The subjects
were Caucasian and were either atopic with allergic rhino-
conjunctivitis symptoms, or non-atopic. The diagnosis of
birch-induced allergic rhinitis was based on a history of
spring seasonal allergic rhinitis, clinical examination, and
skin prick test positivity according to ARIA-guidelines (1).
Characteristics of the subject groups are shown in Table 1.
Exclusion criteria were smoking, acute respiratory infection
during the experiment, other diseases than allergic rhinocon-
junctivitis, regular use of medication, as well as nasal endo-
scopic ﬁndings of moderate or severe septal deviation, nasal
polyps, or mucopurulent discharge.
Nasal challenge and biopsies
The subjects participated in the challenge experiment in
January, which is the season with no ﬂowering outdoor
plants in Finland. The local anesthesia and biopsy tech-
niques have been previously described (32). Brieﬂy, the
ﬁrst biopsy was taken with Fokkens0 forceps from the
anterior edge of the right inferior turbinate before the
challenge. The challenge was performed by putting 3–5
drops of either birch pollen solution (Betula Verrucosa,
Alutard SQ, 10 000 SQ-U, ALK-Abello, Hørsholm, Den-
mark) or diluent (ALK-Diluent; ALK-Abello) on the left
nasal inferior turbinate. The second biopsy was taken
from the left inferior turbinate 3 min after challenge. The
patients were asked not to use medication (antihistamine
and/or nasal corticosteroids) for a minimum of 5 days
before specimens were taken. However, all subjects
reported that they had not needed to use medication for a
longer time than 4 weeks before the specimens were taken.
Symptoms scores
The patients were asked the following symptoms before
and 20 min after taking the biopsies: nasal and eye itch-
Table 1. The antibodies (all IgG) and their concentrations
used in immunohistochemistry for detecting TLR 1-7 and
9-10 proteins. The mAb anti-TLR8 was not commercially
available when the work was performed, and thus was not
used
TLR1 (H-90):sc-30000 Santa Cruz Biotechnology, Inc.,
Dallas, Texas, USA, 1:100, 2 lg/mL
TLR2 (H-175):sc-10739 Santa Cruz Biotechnology, Inc.,
1:50, 4 lg/mL
TLR3 (H-125):sc-10740 Santa Cruz Biotechnology, Inc.
1:50, 4 lg/mL
TLR4 (H-80):sc-10741 Santa Cruz Biotechnology, Inc.
1:50, 4 lg/mL
TLR5 (IMG-664A) Imgenex, San Diego, California, USA,
1:200, 2.5 lg/mL
TLR6 (IMG-304A) Imgenex, 1:3000, 0.17 lg/mL
TLR7 (IMG-581A) Imgenex, 1:300, 1.67 lg/mL
TLR9 (H-100):sc-25468 Santa Cruz Biotechnology, Inc.
1:100, 2 lg/mL
TLR10 (DDX0490) Dendritics, Lyon, France, 1:200,
2.5 lg/mL
MyD88 (ab2068) Abcam, Cambridge, UK, 1:800, 1.25 lg/
mL
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ing; nasal congestion, discharge, sneezing, pain, and bleed-
ing. The scores for itching symptoms and congestion-dis-
charge-sneezing symptoms were used in this study. These
two scores were determined from the asked corresponding
symptoms semiquantitatively 0 (no symptoms), 1 (mild), 2
(moderate), 3 (severe).
Immunohistochemistry and light microscope
evaluation
The nasal biopsies were formalin-ﬁxed and paraﬃn-embed-
ded. Four lm sections of paraﬃn blocks were deparaﬃnized
in xylene and rehydrated in decreasing concentration of etha-
nol to distilled water. Slides were pretreated in a PreTreat-
ment module (Lab Vision Corp., Fremont, CA, USA) in
Tris-HCl (pH 8.5) for antigen retrieval and stained in an
Autostainer 480 (Lab Vision Corp.). Primary antibodies are
listed in Table 1. For detection of bound antibodies Dako
REAL EnVision Detection system, Peroxidase/DAB+, Rab-
bit/Mouse (Dako, Glostrup, Denmark) was used. Slides
were counterstained with hemalaun-eosin. Mucosa of the
oral and nasal cavities, placenta and pancreas served as posi-
tive controls. The speciﬁcity of immunohistochemistry was
controlled by omitting the primary antibodies. Two
researchers (JR and JH) scored the stained sections indepen-
dently. Cases of disagreement were discussed, and a consen-
sus score was determined for further analysis. The staining
score was determined semiquantitatively from the samples: 0
(no positively stained cells); 1 (< 5–20% of the cells were
positive); 2 (20–50% of the cells were positive); 3 (> 50–80%
of the cells were positive); 4 (80–100% of the cells were posi-
tive). For data analyses, we used the staining scores and the
delta staining scores. The delta staining score was counted in
the following way: the delta staining score – staining score
postchallenge – staining score prechallenge. Inﬂammation in the
nasal specimens was based on the semiquantitatively
assessed amount of inﬂammatory cell (lymphocyte and poly-
morphonuclear leukocyte) inﬁltration in the mucosa, and
was scored by: 0 = no inﬂammation, 1 = mild inﬂammation,
2 = moderate inﬂammation, 3 = strong inﬂammation.
mRNA levels of TLR1-10
For the RNA-microarray assay, we used nasal biopsies
taken from six healthy and seven allergic subjects before
and 3 min after the intranasal birch or diluent challenge.
For RNA isolations Rneasy Mini kit (Qiagen, Hilden,
Germany) was used according to the instructions of the
manufacturer. RNA integrity and quantity were measured
with AgilentBioanalyser RNA 6000 Nano kit and Nano-
Drop spectrophotometer, respectively. The processed
RNA samples were prepared and hybridized on Illumina
human WG-6 v2 chips in Finnish DNA Microarray Cen-
tre (Turku Centre for Biotechnology, Turku, Finland).
Chipster analysis software was used for basic statistics and
data normalization (quantile) purposes and IPA software
(Ingenuity; Qiagen) comparing the groups of samples and
interpreting the data, respectively (33).
Data analysis
Statistical analysis was carried out by the PASW statistics
18.0 Statistical Software Package (SPSS Inc., Chicago, IL,
USA). Data are expressed as means and as medians when
speciﬁed. For comparisons, the results were analyzed by,
Fisher’s exact test (discrete) or Kruskal–Wallis and
Mann–Whitney U (MWU) tests (continuous). For pair-
wise comparisons Wilcoxon test was used. Two-tailed p-
values of < 0.05 were considered statistically signiﬁcant.
RESULTS
The baseline nasal epithelial expression of TLR
proteins in healthy and allergic subjects
The atopic and control groups did not diﬀer by
age, male-female ratio, or by number and percent-
age of peripheral blood eosinophils (p < 0.05,
Table 2). Atopic patients had signiﬁcantly
increased total IgE, birch speciﬁc IgE, and timothy
speciﬁc IgE levels in serum (Table 2). We detected
expression of TLR 1-7 and 9-10 proteins in nasal
epithelial layer and glandular epithelial cells
(Figs 1 and 2). In addition, mild expression of
TLR 3 and TLR5-7 was detected in mucosal leu-
kocytes and endothelial cells. In this study we
focused on the epithelial expression. In winter and
before challenge, median epithelial staining scores
of TLR 1-7 and TLR 9-10 proteins did not diﬀer
between the atopic and control groups (p > 0.05,
by Mann–Whitney U-test, data not shown). The
expression of TLR1 was moderate and granular,
and mostly found in the lower half of the nasal
epithelium. The expression of TLR2 was weak and
found close to nuclei, whereas that of TLR3 was
strong, granular and detected in all epithelial com-
partments. The expression of TLR4 and TLR5
was moderate and unevenly distributed in the epi-
thelium. Interestingly, a strong expression of TLR6
was found throughout the whole nasal epithelium
in both groups. A moderate TLR7 expression was
mainly detected in the vicinity of the nucleus bor-
ders. The expression of TLR9 and TLR10 was
moderate and granular throughout all nasal epithe-
lial layers. The expression of MyD88 was patchy
and varied from moderate to strong. Atopic female
subjects had a lower staining score of TLR2, med-
ian (min–max) 0 (0–1); than atopic male subjects 1
(1–3) (p = 0.04, by Fisher0s exact test, data not
shown). There were no other gender- or age-
related diﬀerences in the baseline expression of
TLR proteins (p > 0.05 by Fisher0s exact and
Mann–Whitney U-tests correspondingly, data not
shown).
The nasal epithelial expression of TLR proteins and
genes after challenge
After intranasal challenge with birch pollen solu-
tion, the median staining score of TLR6 was signiﬁ-
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cantly lower in the atopic group contrasted to the
healthy group (p = 0.02, Fig. 3), whereas no diﬀer-
ence was observed after the diluent challenge. No
diﬀerences were observed in the expression of
TLR1-5, TLR7, TLR9-10, and MyD88 between the
groups. There was no change in the median stain-
ing score of TLR1-7 and 9-10 proteins between
nasal biopsies taken before and 3 min after the
intranasal challenge in winter (p > 0.05, by Wilco-
xon test, data not shown). The ﬁnding was similar
in control and allergic groups, and after challenge
with either birch pollen or diluent drops. The med-
ian delta staining scores of TLR1 and TLR6 were
signiﬁcantly lower in the atopic compared to the
control group, but only after challenge with birch
pollen (p = 0.04 both, Fig. 3). Interestingly, after
the diluent challenge, the median delta staining
score of TLR5 in the atopic group was 0 indicating
no change, whereas in the control group it was 1.5
reﬂecting an increased TLR5 expression (p = 0.03
Fig. 3). The median delta staining scores of TLR2-
5, TLR7, TLR9-10, and MyD88 did not diﬀer
between control and atopic groups, after challenge
with birch pollen solution (p > 0.05, by Mann–
Whitney U-test, data not shown). After the chal-
lenge with a diluent solution, the median delta
staining scores of TLR1-4, TLR6-7, TLR9-10, and
MyD88 did not diﬀer between the control and ato-
pic groups (p > 0.05, by Mann–Whitney U-test,
data not shown). When comparing nasal biopsies
taken from the same individuals before and after
the challenge with either diluent or birch pollen
Table 2. Patient characteristics. Q1 and Q3 indicate 25% and 75% percentiles, respectively. p-values by Fisher0s exact test
(continuous variables); or by Kruskal–Wallis and Mann–Whitney U-tests (dichotomous variables)
Control Atopy p-Value
N = 10 N = 9
Age
Median 23 24 0.82
Min–max 22–36 22–34
No. of male sex 3 3 1.00
Blood eosinophil count (109/L)
Median 0.09 0.13 0.66
Q1–Q3 0.08–0.19 0.10–0.24
Serum total IgE (IU/mL)
Median 27.0 98.0 0.013
Q1–Q3 11.5–72.0 57.0–694.0
S-IgE birch(IU/mL)
Median <0.35 12.0 0.001
Q1–Q3 <0.35–<0.35 8.0–192.5
S-IgE timothy grass(IU/mL)
Median <0.35 5.9 0.002
Q1–Q3 <0.35–<0.35 3.5–16.5
No. subjects with positive SPT reaction to
Any aeroallergen 0 9 <0.001
Birch pollen 0 9 <0.001
Timothy grass pollen 0 5 0.008
Other grass pollen 0 7 <0.001
Animal dander 0 5 0.008
House dust mite 0 0 1.00
Other aeroallergens 0 0 1.00
No. patients challenged with
Diluent 4 3 1.00
Birch 6 6
Itching symptom score median (min–max)
Before challenge 0 (0–0) 0 (0–0) 1.00
After diluent 0 (0–0) 0 (0–0) 1.00
After birch 0 (0–0) 1 (0–2) 0.001
Congestion-discharge-sneezing score median (min–max)
Before challenge 0 (0–0) 0 (0–0) 1.00
After diluent 0 (0–1) 1 (0–1) 0.49
After birch 0 (0–1) 0.5 (0–1) 1.00
Mucosal inﬂammation score median (min–max)
Before challenge 1 (0–2) 1 (1–2) 1.00
After diluent 2 (1–2) 2 (1–2) 1.00
After birch 1 (0–2) 1.5 (1–2) 0.55
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Fig. 1. The baseline expression of the TLR1-7 and TLR9-10 proteins in the nasal epithelium from healthy controls (Con-
trol) and subjects with birch pollen allergic rhinitis (Allergy) during winter. Magniﬁcation 9100 in all panels, except in
TLR2 A, TLR 3 Control and Allergy; and TLR6 Allergy, where magniﬁcation is 9200.
A B
C D
Fig. 2. The intra-epithelial expression of TLRs. The expression of TLR2 (A) is weak close to nuclei. The expression of
TLR4 (B) is moderate and unevenly distributed in the epithelium. The expression of TLR9 (C) and TLR10 (D) is granular
throughout the epithelium. Magniﬁcation is 9600 in all panels.
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allergen drops the median staining scores of TLR
1-7 and 9–10 proteins, and MyD88 did not diﬀer
(p > 0.05, by Wilcoxon test, data not shown).
The fold change values of TLR 1-10 mRNAs
ranged between 0.89 and 1.07, which indicates very
slight changes on mRNA levels after challenge
(Fig. 4). The median fold change of TLR8 mRNA
was statistically signiﬁcantly higher in allergic than
control subjects after challenge with birch pollen,
however the changes in TLR8 mRNA levels
remained very slight and thus the diﬀerence was
not biologically signiﬁcant (Fig. 4H).
Symptom scores and inflammation scores
In winter, the baseline median score for itching
symptoms and for congestion-discharge-sneezing
symptoms was identical in the control and atopic
groups (p > 0.05 both, Table 2). Accordingly, the
oﬀ-seasonal baseline inﬂammation score of the
biopsies was identical in both groups (p > 0.05 in
both, Table 2). There were no change in the median
inﬂammation scores when comparing specimens
taken from the same individual before and 3 min
after challenge with either diluent or birch, neither
in controls nor in atopics (p > 0.05 all, by Wilco-
xon test, data not shown). The median score for
itching symptoms asked 20 min after birch chal-
lenge, was signiﬁcantly higher in the atopic than in
the control group, whereas no diﬀerence was
detected after diluent challenge (p < 0.001, p = 1.00
correspondingly, Table 2). In contrast, all subjects
reported postchallenge nasal pain/irritation, dis-
charge, or slight bleeding, probably due to biopsy-
taking. Thus, there were no postchallenge diﬀer-
ences between the atopic and control group in med-
ian score for congestion-discharge-sneezing
symptoms (p > 0.05, Table 2). None of the subjects
reported dyspnea after challenge.
DISCUSSION
In this study we showed that TLR 1-7 and 9-10
proteins are expressed in nasal epithelium. The
TLR3, 6, 7, 10 proteins had the strongest nasal epi-
thelial expression, whereas TLR2 had the mildest.
TLR1, 2, 4, 5, 6, 10 proteins have previously been
reported to be located in the plasma membrane;
however we also detected them in the intracellular
compartments of epithelial cells (8). Tengroth et al.
demonstrated by RTq-PCR, immunohistochemistry
and ﬂow cytometry that nasal apical epithelium
expresses abundantly TLR3, TLR7, TLR9, RIG-I,
and MDA-5. Moreover, they showed by ELISA
upregulated cytokines (IL-6, GMCSF, IL-8, IFN-b)
in the nasal mucosa after stimulation of several
TLR-agonists, which suggests that epithelial TLR
and RLR receptors might mediate nasal viral
response and thus could be important in exacerba-
tions (34). Bielinska et al. administered intranasally
anthrax antigen with a nanoemulsion to mice. This
Fig. 3. The expression of TLR6 in the nasal epithelium from a healthy subject (Control) and a birch pollen allergic
(Allergy) subject in winter. The expression of TLR6 decreased signiﬁcantly in the allergic group after the birch pollen chal-
lenge. Prechallenge – the nasal biopsy was taken before intranasal challenge with the birch pollen solution. Postchallenge –
the nasal biopsy was taken 3 min after intranasal challenge with the birch pollen solution. Magniﬁcation 9200 in all
panels.
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induced TLR2 and TLR4 activation along with a
MyD88-independent antibody response and a
MyD88-dependent Th-1 and Th-17 cell-mediated
immune response (35). The ﬁnding might be used
in the development of mucosal vaccines. Ioannidis
et al. (36) demonstrated that TLR6 has a basolater-
al location in human tracheal epithelium which is
in accordance to our observation in the nasal epi-
thelium. TLR2-6 proteins have been demonstrated
to have the strongest expression in the airway epi-
thelium while the expression of TLR7-10 ﬂuctuates
depending on the cell type studied (5).
We previously demonstrated that birch pollen is
actively transported through the epithelium within
1 min (31). In this study, we detected early
changes in the expression of epithelial TLR1 or
TLR6 after the birch pollen allergen challenge sug-
gesting, that the challenge could putatively modify
the structure of epithelial TLR1 or TLR6 proteins
in atopic subjects leading to decreased binding of
anti-TLR1 and anti-TLR6 antibodies to their epi-
topes. Thus, birch pollen allergen entry would
putatively be regulated by TLR1 and TLR6 medi-
ated pathways. The ﬁnding that mRNA expression
was not aﬀected after the challenge, could in part
be explained by the fact that whole biopsies were
used instead of epithelial cells. Our future aim
would be to observe if birch exposure aﬀected the
activity of TLR proteins; or noncoding RNAs reg-
ulating TLR protein synthesis.
Fransson et al. demonstrated mRNA and protein
expression of TLRs 2, 3, and 4 in the nasal mucosa
both in subjects with and without birch and/or tim-
othy pollen allergy, which is in accordance to our
results (29). Probably partly due to diﬀerences in
the study set up, they demonstrated a more apical
location of TLR3 and an increase in expression of
TLRs 2, 3, 4 proteins following the allergen chal-
lenge pre-season, but an increase only in TLR3
mRNA during the pollen season (29).
Tengroth et al. have analyzed by ﬂow cytome-
try and Luminex na€ıve nasal polyp and turbinate
tissues, as well as human tissues after in vivo and
in vitro stimulation with a TLR9 agonist, CpG.
Interestingly, epithelial expression of TLR9 was
detected in turbinates from healthy controls and
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Fig. 4. The immunohistochemical delta staining scores of TLR proteins (A–C) and TLR mRNA fold changes (E–H).
Diluent chall. – intranasal challenge with diluent solution; Birch chall. – intranasal challenge with birch pollen solution.
The staining score – proportion of positively stained cells/specimen (from 0 to 4). The delta staining score = staining
score postchallenge – staining score prechallenge. Only the TLR proteins with statistically signiﬁcantly diﬀerent delta staining
scores between control (Control) and birch pollen allergic (Allergy) subjects are shown: TLR1 (A), TLR5 (B), and TLR6
(C). The mRNA fold change = relative mRNA abundancy postchallenge: relative mRNA abundancy prechallenge. The fold
changes of TLR1 (E), TLR5 (F), TLR6 (G), and TLR8 (H) mRNAs. The levels of total and birch speciﬁc IgE Ab of
serum. (D) *p < 0.05, **p < 0.01, ***p < 0.001, by Mann–Whitney U-test.
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in polyp tissue, whereas TLR9 was absent in tur-
binates from CRSwNP patients. CpG stimulation
resulted in an upregulation of TLR9 and modula-
tion of cytokines in turbinate tissue from patients,
suggesting that defects in the TLR9 mediated
microbial defense in the turbinate might explain
virus-induced polyp growth (37).
Several studies have observed TLRs in the ato-
pic lower airway inﬂammation. TLR2-TLR7 pro-
teins have been detected in patients with severe
asthma (38). Subcutaneous QbG10, a TLR9 ago-
nist, improved symptoms and lung function in
patients with allergic asthma (39). Another pla-
cebo-controlled trial showed that repeated intrana-
sal TLR7 agonist AZD8848 reduced symptoms in
patients with birch and/or grass pollen allergic rhi-
nitis, but it produced reversible blood lymphocyte
reduction and dose-dependent ﬂu-like symptoms as
side-eﬀects (28). Intranasal TLR9 agonist CpG
increased, whereas TLR7 agonist, R848, decreased
airway inﬂammation in mice with established aller-
gic inﬂammation (40). Parsons et al. (41) showed
that primary bronchial epithelial cells from asthma
patients were able to up-regulate TLR3, following
infection, but failed to initiate an eﬀective innate
immune response. Deiﬂ et al. stimulated in vitro
monocytes and monocyte-derived dendritic cells
from allergic patients with TLR ligands. They
found that TLR ligands except ﬂagellin enhanced
Bet v 1 –allergen uptake (42). Our ﬁnding that the
diluent challenge in controls induced expression of
TLR5, which usually recognizes ﬂagellin, requires
further evidence to be explained.
In mice, allergic rhinitis response to house dust
mite might result from TLR2 signaling axis in the
nasal mucosa, whereas in the lung mucosa the aller-
gic asthma response occurs predominantly via TLR4
signaling axis (43). Intranasally administered TLR3
or TLR4 ligands induced relatively similar murine
airway hyper-responsiveness and cellular inﬁltration
in lungs (44). TLR2 agonist, Pam3Cys, induced an
asthma exacerbation in mice, but had, on the other
hand, long-term protective eﬀect on secondary aller-
gic responses in the airways (45).
The TLR-family with eleven members explodes
in four-ﬁgure numbers when observing single
nucleotide polymorphism, expression variants, and
post-translational modiﬁcation (46). Two meta-
analyses of genome-wide association studies have
shown that loci in TLR1-TLR6-TLR10 region
associate with allergic sensitization; or self-
reported cat, dust mite, or pollen allergies (23,
24). Single nucleotide polymorphism in the TLR1,
6, 7, 8 genes might associate with grass and/or
birch pollen allergic rhinitis; of which the associa-
tion between TLR7-8 gene variants and grass pol-
len allergic rhinitis was more pronounced (26,
27). Other studies have shown that polymor-
phisms or defects in TLR1-2, TLR6-7, TLR9-10
genes, and MyD-88 dependent pathways seem to
associate with atopic asthma (13, 47–49). Our
ﬁndings of epithelial TLR1-2, TLR6, TLR9, and
MyD88 having putatively a role in birch pollen
allergic responses is consistent with these observa-
tions. Future evidence is still needed of gene-envi-
ronmental interactions aﬀecting the TLR
pathways in airway allergy.
Our results should be interpreted with caution
because of the small number of patients studied. The
usage of the whole biopsies and short challenge time,
might have in part aﬀected the results. We also
acknowledge the fact that the eﬀect of multiple test-
ing could limit the signiﬁcance of the results.
CONCLUSIONS
The TLR protein family is widely located in the
human nasal epithelium, which most probably reﬂects
to the active innate immunity functions of nasal epi-
thelium. Findings of altered TLR1 and TLR6 protein
expression after birch pollen challenge still require to
be validated on the protein activity level.
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